A pair of investors will acquire bluebird bio in a deal worth only $29 million upfront after the gene therapy maker ran out ...
Teva and its partner Alvotech on Friday followed Amgen in launching a biosimilar to J&J's blockbuster immunosuppressive ...
The FDA said Friday that the shortage of semaglutide, the main ingredient in Novo Nordisk’s GLP-1 drugs Ozempic and Wegovy, ...
Pfizer ends commercialization of Beqvez hemophilia B gene therapy. CEO Kim Phelan of Coalition for Hemophilia B expresses ...
UnitedHealthcare offers voluntary buyouts to 30,000 employees due to low attrition and digital shift, COO Michael Baker tells ...
Eli Lilly has amassed a stockpile of soon-to-be-launched drugs and related materials, primarily its oral GLP-1 candidate ...
Lawyers for the government gave the first substantive signal that the Trump administration will continue to defend Medicare ...
As he was testing new antivirals to halt a future pandemic, John Chodera encountered an unlikely set of new problems that ...
A meeting of CDC vaccine advisors has been postponed, according to a senior HHS official. “The ACIP meeting will ...
Charles River Labs beats Q4 estimates, Theratechnologies resumes Egrifta SV distribution, FDA greenlights BCG alternative, ...
The FDA on Friday approved Mirum Pharmaceuticals' Ctexli to treat adults with cerebrotendinous xanthomatosis (CTX), a rare, progressive and genetic disease.
Celia Witten, deputy director of the FDA's Center for Biologics Evaluation and Research, has left the FDA, adding to a wave of departures at the agency and across the federal health infrastructure as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback